For an early-stage biotech, the decisions made now will shape the future of the company and can determine long-term success or failure. From day one, the pressure is on to rapidly progress towards milestones and demonstrate value to investors and other stakeholders. But while time is of the essence, this fast pace must be effectively balanced with risk mitigation.

Companies are faced with making a strategic assessment of how best to balance speed and risk and the impact of that decision. An experienced contract development and manufacturing organization (CDMO) can help guide you through the different stages of drug development and identify opportunities to accelerate timelines while ensuring that risk is properly mitigated, and quality is not compromised.

Download our ebook and learn about four areas of development where we have applied this strategy for customers.

• Accelerating identification of high-performing cell lines
• Streamlining analytical methods development and implementation
• Reducing host cell proteins
• Scaling a process directly from 3L to 2000L​

Identifying the right outsourcing partner can increase the odds of success for your company, your investors and ultimately, patients with unmet medical needs. We provide integrated CDMO services, offering adaptive solutions through our BioReliance® End-to-End Solutions.
​

*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.